Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results

Rhea-AI Summary

Hims & Hers Health, Inc. reported Q2 2021 revenue of $60.7 million, a 69% increase year-over-year. The net loss widened to $(9.2) million compared to $(1.0) million a year earlier, despite a gross margin improvement to 78%. Subscriptions rose to 453,000, with 786,000 net orders recorded. The company's acquisitions of Apostrophe and Honest Health are anticipated to accelerate growth in new markets. For Q3 2021, revenue guidance is set at $69-$71 million, with Adjusted EBITDA forecasted at $(9)-(11) million for the quarter and $(35)-(40) million for the full year.

Positive

• Revenue increased by 69% year-over-year to $60.7 million.
• Gross margin improved to 78% from 71% year-over-year.
• Net orders reached 786,000, a significant rise from the previous year.
• Acquisitions of Apostrophe and Honest Health expected to drive growth.

Negative

• Net loss increased to $(9.2) million from $(1.0) million year-over-year.
• Adjusted EBITDA declined to $(4.7) million compared to a profit of $1.2 million in Q2 2020.

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported financial results for the second quarter ending June 30, 2021.

"This was a quarter of very strong execution, as we continued to drive consistent organic revenue growth across our business, from our core categories to the newer mental health services" said Andrew Dudum, CEO and co-founder of Hims & Hers. "We also heavily invested in key infrastructure and differentiated technologies. These are long-term plays to drive financial improvement and create durable advantage."

Mr. Dudum continued, "Our vision for the future is simple. We are building Hims & Hers into the new front door to healthcare. A new front door that will span dozens of medical specialties, welcoming customers of all demographics into a unified consumer platform that looks and feels and talks to them in a way that gives them confidence they’re in the right hands. I believe the majority of healthcare delivery will begin on a platform like ours in the future. For that reason, everything we do is in service of an opportunity that we believe will continue to accelerate and grow over years, both in the US and overseas."

As previously announced, Hims & Hers recently completed the acquisitions of Apostrophe, a teledermatology specialist and compounding pharmacy, and Honest Health, a London-based vertical health platform. Hims & Hers believes these acquisitions will accelerate growth in nascent geographies and specialty verticals. Additional information on the transactions can be found in our most recent Quarterly Report on Form 10-Q.

Key Business Metrics (In Thousands, Except AOV)
	June 30, 2021				March 31, 2021				December 31, 2020				September 30, 2020				June 30, 2020
AOV (three months period)	$	74			$	74			$	69			$	67			$	58
Net Orders (three months period)	786				687				579				582				572
Subscriptions (end of period)	453				391				312				283				258

Revenue (In Thousands, Unaudited)
	Three Months Ended
	June 30, 2021				March 31, 2021				December 31, 2020				September 30, 2020				June 30, 2020
Online Revenue	$	58,146			$	50,680			$	40,091			$	38,829			$	33,284
Wholesale Revenue	2,546				1,634				1,375				2,495				2,620
Total revenue	$	60,692			$	52,314			$	41,466			$	41,324			$	35,904
Total revenue year-over-year growth	69		%		74		%		67		%		91		%		76		%

• Revenue was $60.7 million for the second quarter 2021 compared to $35.9 million for the second quarter 2020, an increase of 69% year-over-year.
• Net loss was $(9.2) million for the second quarter 2021 compared to $(1.0) million for the second quarter 2020.
• Gross margin was 78% for the second quarter 2021 compared to 71% for the second quarter 2020.
• Adjusted EBITDA was $(4.7) million for the second quarter 2021 compared to $1.2 million for the second quarter 2020.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States ("U.S. GAAP"), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading "Non-GAAP Financial Measures".

Financial Outlook

Hims & Hers provides guidance based on current market conditions and expectations for revenue and Adjusted EBITDA, which is a non-GAAP financial measure. The guidance below includes the expected impact the acquisitions of Honest Health and Apostrophe will have on our consolidated financial results.

For the third quarter 2021, we expect:

• Revenue to be in the range of $69 million to $71 million.
• Adjusted EBITDA to be in the range of $(9) million to $(11) million.

For the full year 2021, we expect:

• Revenue to be in the range of $251 million to $255 million.
• Adjusted EBITDA to be in the range of $(35) million to $(40) million.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the second quarter 2021 results on August 11, 2021, at 5:00 p.m. ET. The conference call can be accessed by dialing (833) 900-2256 for U.S. participants and (236) 714-2727 for international participants, and referencing conference ID #9972259. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide access to quality, convenient and affordable care for all Americans. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "potential," "projects," "predicts," "continue," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, our expected future financial and business performance, the assumptions underlying such statements, statements about events and trends including events and trends that we believe may affect our financial condition, results of operations, short- and long-term business operations and objectives, and financial needs, our expectations regarding market acceptance, user experience, the success of our business model, the growth of certain of our categories and the impact of our recent acquisitions, our ability to expand the scope of our offerings, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to the healthcare industry. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the "Risk Factors" section of our most recently filed Annual Report on Form 10-K for the year ended December 31, 2020, as amended, our most recent Quarterly Report on Form 10-Q, and our subsequent filings with the Securities and Exchange Commission (the "Commission").

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our annual report on Form 10-K for the year ended December 31, 2020, as amended, our most recent Quarterly Report on Form 10-Q, and our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

Average Order Value ("AOV") is defined as Online Revenue divided by Net Orders (each as defined below).

"Net Orders" are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

"Online Revenue" represents the sales of products and services on our platform, net of refunds, credits, chargebacks and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve.

"Subscriptions" are defined as the number of customer agreements where the customer has agreed to be automatically billed on a recurring basis at a defined cadence. The billing cadence is typically defined as a number of months (for example, billed every month or every three months). Subscriptions are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscription billing is preferred by many of our customers because most of the products we make available treat chronic conditions and these product offerings are most effective when taken consistently and continuously. Customers can cancel subscriptions in between billing periods to stop receiving additional products and can reactivate subscriptions to continue receiving additional products.

"Wholesale Revenue" represents non-prescription product sales to retailers through wholesale purchasing agreements.

CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Share and Per Share Data)
	June 30, 2021				December 31, 2020
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	107,145			$	27,344
Short-term investments	210,178				72,864
Inventory	6,590				3,543
Prepaid expenses and other current assets	12,429				5,404
Deferred transaction costs	—				3,929
Total current assets	336,342				113,084
Restricted cash	856				1,006
Other long-term assets	7,762				4,607
Goodwill	2,739				—
Total assets	$	347,699			$	118,697
Liabilities, mezzanine equity, and stockholders' equity (deficit)
Current liabilities:
Accounts payable	$	15,564			$	8,066
Accrued liabilities	10,761				4,984
Deferred revenue	1,019				1,272
Warrant liabilities	—				906
Total current liabilities	27,344				15,228
Warrant liabilities	25,406				—
Other long-term liabilities	1,895				381
Total liabilities	54,645				15,609
Commitments and contingencies
Mezzanine equity:
Redeemable convertible preferred stock par value $0.0001, 275,000,000 and 95,997,674 shares authorized and nil and 93,328,118 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively; liquidation preference of nil and $268,452 as of June 30, 2021 and December 31, 2020, respectively	—				249,962
Total mezzanine equity	—				249,962
Stockholders' equity (deficit):
Common stock – Class A shares, par value $0.0001, 2,750,000,000 and 166,696,759 shares authorized and 184,866,219 and 46,025,754 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of June 30, 2021; Class F shares, par value $0.0001, 6,941,352 shares authorized, issued, and outstanding as of December 31, 2020	19				—
Additional paid-in capital	524,924				24,429
Accumulated other comprehensive loss	(40		)		(11		)
Accumulated deficit	(231,849		)		(171,292		)
Total stockholders' equity (deficit)	293,054				(146,874		)
Total liabilities, mezzanine equity, and stockholders' equity (deficit)	$	347,699			$	118,697

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In Thousands, Except Share and Per Share Data, Unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2021				2020				2021				2020
Revenue	$	60,692			$	35,904			$	113,006			$	65,967
Cost of revenue	13,415				10,242				25,482				19,686
Gross profit	47,277				25,662				87,524				46,281
Gross margin %	78		%		71		%		77		%		70		%
Operating expenses:(1)
Marketing	27,944				11,800				54,902				24,573
Selling, general, and administrative	36,740				14,841				98,438				28,905
Total operating expenses	64,684				26,641				153,340				53,478
Loss from operations	(17,407		)		(979		)		(65,816		)		(7,197		)
Other income (expense):
Change in fair value of liabilities	7,963				(21		)		5,282				50
Interest expense	—				—				—				(10		)
Other income, net	325				56				101				215
Total other income	8,288				35				5,383				255
Loss before provision for income taxes	(9,119		)		(944		)		(60,433		)		(6,942		)
Provision for income taxes	(34		)		(37		)		(124		)		(72		)
Net loss	(9,153		)		(981		)		(60,557		)		(7,014		)
Other comprehensive income (loss)	32				24				(29		)		(18		)
Total comprehensive loss	$	(9,121	)		$	(957	)		$	(60,586	)		$	(7,032	)
Net loss per share attributable to common stockholders:
Basic and diluted	$	(0.05	)		$	(0.03	)		$	(0.35	)		$	(0.20	)
Weighted average shares outstanding:
Basic and diluted	191,922,517				35,331,373				172,631,312				34,968,882

(1) Includes stock-based compensation expense as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2021				2020				2021				2020
Marketing	$	772			$	367			$	2,618			$	658
Selling, general, and administrative	8,388				1,558				40,772				2,671
Total stock-based compensation expense	$	9,160			$	1,925			$	43,390			$	3,329

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands, Unaudited)
	Six Months Ended June 30,
	2021				2020
Operating activities
Net loss	$	(60,557	)		$	(7,014	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	899				392
Stock-based compensation	43,390				3,329
Change in fair value of liabilities	(5,282		)		(50		)
Warrant expense in connection with Merger	154				—
Amortization of debt issuance costs	144				167
Non-cash other	959				(19		)
Changes in operating assets and liabilities:
Inventory	(3,047		)		(2,004		)
Prepaid expenses and other current assets	(4,635		)		(950		)
Other long-term assets	(58		)		733
Accounts payable	7,353				(1,061		)
Accrued liabilities	5,583				741
Deferred revenue	(253		)		264
Other long-term liabilities	3				126
Net cash used in operating activities	(15,347		)		(5,346		)
Investing activities
Purchases of investments	(187,521		)		(48,908		)
Maturities of investments	48,421				34,090
Proceeds from sales of investments	1,215				9,800
Investment in website development and internal-use software	(1,833		)		(1,050		)
Purchases of property, equipment, and intangible assets	(122		)		(801		)
Acquisition of business, net of cash acquired	(748		)		—
Net cash used in investing activities	(140,588		)		(6,869		)
Financing activities
Proceeds from issuance of redeemable convertible preferred stock	—				37,552
Pre-closing stock repurchase	(22,027		)		—
Proceeds from issuance of common stock upon Merger	197,686				—
Proceeds from PIPE	75,000				—
Payments for transaction costs	(12,851		)		—
Proceeds from repayment of promissory notes associated with vested and unvested shares	1,193				—
Proceeds from exercise of Class A common stock warrants	808				—
Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations	254				45
Repayments of principal on term loan	—				(1,515		)
Payments for taxes related to net share settlement of equity awards	(4,458		)		—
Net cash provided by financing activities	235,605				36,082
Foreign currency effect on cash and cash equivalents	(19		)		(12		)
Increase in cash, cash equivalents, and restricted cash	79,651				23,855
Cash, cash equivalents, and restricted cash at beginning of period*	28,350				22,797
Cash, cash equivalents, and restricted cash at end of period*	$	108,001			$	46,652
Supplemental disclosures of cash flow information
Cash paid for taxes	$	227			$	197
Cash paid for interest	—				10
Non-cash investing and financing activities
Expiration of Class A common stock redemption right	$	—			$	4,500
Exercise of convertible preferred stock warrants	—				3,840
Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase	125				—
Conversion of redeemable convertible preferred stock to common stock	249,837				—
Assumption of Merger warrants liability	51,814				—
Exercise of Class A common stock warrants	20,872				—
Reclassification of deferred transaction costs	3,929				—
Conversion of Series D preferred stock warrants to Class A common warrants	1,160				—
Change in transaction costs payable	568				—
Vesting of early exercised stock options	106				20
Common stock issued, contingent consideration, and payables for acquisition of business	4,064				—
Equity awards classified as prepaid expenses	2,500				—

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (as defined below), a non-GAAP financial measure. We use Adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, when taken together with the corresponding U.S. GAAP financial measure, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. A reconciliation is provided below for Adjusted EBITDA to net loss, the most directly comparable financial measure stated in accordance with U.S. GAAP. Investors are encouraged to review net loss and the reconciliation of Adjusted EBITDA to net loss, and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net loss before depreciation and amortization, provision for income taxes, interest income, interest expense, amortization of debt issuance costs, stock-based compensation, change in fair value of warrant liability, one-time bonuses and warrant expense in connection with the combination of Hims, Inc. ("Hims") and Oaktree Acquisition Corp. ("OAC"), with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the "Merger"), and acquisition-related costs, which include professional services and consideration paid for employee equity with vesting requirements incurred directly as a result of acquisitions.

Net Loss to Adjusted EBITDA Reconciliation (In Thousands, Unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2021				2020				2021				2020
Net loss	$	(9,153	)		$	(981	)		$	(60,557	)		$	(7,014	)
Depreciation and amortization		505				212				899				392
Provision for income taxes		34				37				124				72
Interest income		(113	)			(108	)			(195	)			(350	)
Interest expense		—				—				—				10
Amortization of debt issuance costs		—				83				144				167
Stock-based compensation		9,160				1,925				43,390				3,329
Change in fair value of warrant liability		(7,963	)			21				(5,282	)			(50	)
Merger bonuses		—				—				5,219				—
Warrant expense in connection with Merger		—				—				154				—
Acquisition-related costs		2,872				—				2,872				—
Adjusted EBITDA	$	(4,658	)		$	1,189			$	(13,232	)		$	(3,444	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005825/en/

FAQ

What were Hims & Hers' Q2 2021 financial results?

Hims & Hers reported a Q2 2021 revenue of $60.7 million, a 69% increase year-over-year, with a net loss of $(9.2) million.

How did Hims & Hers' subscriptions perform in Q2 2021?

Subscriptions increased to 453,000 in Q2 2021, compared to 258,000 in Q2 2020.

What is the revenue guidance for Hims & Hers in Q3 2021?

Hims & Hers expects revenue to be in the range of $69 million to $71 million for Q3 2021.

What are the expected impacts of recent acquisitions on Hims & Hers' growth?

Hims & Hers anticipates that the acquisitions of Apostrophe and Honest Health will accelerate growth in new markets.

What is the Adjusted EBITDA forecast for Hims & Hers in 2021?

For the full year 2021, Hims & Hers expects Adjusted EBITDA to range from $(35) million to $(40) million.